| Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine E Smeraldi, R Zanardi, F Benedetti, D Di Bella, J Perez, M Catalano Molecular psychiatry 3 (6), 508-511, 1998 | 811 | 1998 |
| Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene R Zanardi, F Benedetti, D Di Bella, M Catalano, E Smeraldi Journal of clinical psychopharmacology 20 (1), 105-107, 2000 | 433 | 2000 |
| Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression R Zanardi, A Serretti, D Rossini, L Franchini, C Cusin, E Lattuada, ... Biological psychiatry 50 (5), 323-330, 2001 | 294 | 2001 |
| Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity A Serretti, R Zanardi, D Rossini, C Cusin, R Lilli, E Smeraldi Molecular psychiatry 6 (5), 586-592, 2001 | 224 | 2001 |
| How long should pindolol be associated with paroxetine to improve the antidepressant response? R Zanardi, F Artigas, L Franchini, L Sforzini, M Gasperini, E Smeraldi, ... Journal of clinical psychopharmacology 17 (6), 446-450, 1997 | 207 | 1997 |
| Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression R Zanardi, L Franchini, M Gasperini, J Perez, E Smeraldi The American journal of psychiatry 153 (12), 1631-1633, 1996 | 184 | 1996 |
| All roads lead to the default-mode network—global source of DMN abnormalities in major depressive disorder A Scalabrini, B Vai, S Poletti, S Damiani, C Mucci, C Colombo, R Zanardi, ... Neuropsychopharmacology 45 (12), 2058-2069, 2020 | 179 | 2020 |
| Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism A Serretti, C Cusin, F Benedetti, L Mandelli, A Pirovano, R Zanardi, ... American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 137 …, 2005 | 174 | 2005 |
| Tryptophan hydroxylase gene associated with paroxetine antidepressant activity A Serretti, R Zanardi, C Cusin, D Rossini, C Lorenzi, E Smeraldi European Neuropsychopharmacology 11 (5), 375-380, 2001 | 173 | 2001 |
| The C (− 1019) G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings A Serretti, P Artioli, C Lorenzi, A Pirovano, V Tubazio, R Zanardi International Journal of Neuropsychopharmacology 7 (4), 453-460, 2004 | 169 | 2004 |
| Fluvoxamine alone in the treatment of delusional depression. F Gatti, L Bellini, M Gasperini, J Perez, R Zanardi, E Smeraldi The American journal of psychiatry 153 (3), 414-416, 1996 | 159 | 1996 |
| Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial D Rossini, A Lucca, R Zanardi, L Magri, E Smeraldi Psychiatry Research 137 (1-2), 1-10, 2005 | 155 | 2005 |
| Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity C Cusin, A Serretti, R Zanardi, E Lattuada, D Rossini, R Lilli, C Lorenzi, ... International Journal of Neuropsychopharmacology 5 (1), 27-35, 2002 | 151 | 2002 |
| Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study R Zanardi, L Franchini, M Gasperini, A Lucca, E Smeraldi, J Perez Journal of clinical psychopharmacology 18 (6), 441-446, 1998 | 150 | 1998 |
| Early onset of lithium prophylaxis as a predictor of good long-term outcome L Franchini, R Zanardi, E Smeraldi, M Gasperini European archives of psychiatry and clinical neuroscience 249, 227-230, 1999 | 147 | 1999 |
| The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments A Serretti, F Benedetti, R Zanardi, E Smeraldi Progress in Neuro-Psychopharmacology and Biological Psychiatry 29 (6), 1074-1084, 2005 | 141 | 2005 |
| SSRIs antidepressant activity is influenced by Gβ3 variants A Serretti, C Lorenzi, C Cusin, R Zanardi, E Lattuada, D Rossini, R Lilli, ... European Neuropsychopharmacology 13 (2), 117-122, 2003 | 139 | 2003 |
| Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? A double-blind, randomized, sham-controlled trial S Giordani, E Smeraldi, R Zanardi J Clin Psychiatry 66 (12), 1569-1575, 2005 | 136 | 2005 |
| Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study R Zanardi, L Franchini, A Serretti, J Perez, E Smeraldi Journal of Clinical Psychiatry 61 (1), 26-29, 2000 | 133 | 2000 |
| 5-HT2A receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study C Messa, C Colombo, RM Moresco, C Gobbo, L Galli, G Lucignani, ... Psychopharmacology 167, 72-78, 2003 | 125 | 2003 |
